Effect of alcohol on clinical complications of hepatitis virus-induced liver cirrhosis: a consecutive ten-year study

Table 7 Relation between antiviral treatment and the odds of EGVB in HBV, ALD + HBV and ALD + HCV patients

Variables	n (%)	OR	95% CI	P value
HBV
No AVT	985/3302 (29.8)	1
AVT	57/399 (14.3)	0.39	0.29–0.52	< 0.001
HCV
No AVT	51/109 (46.8)	1
AVT	36/157 (22.9)	0.34	0.20–0.57	< 0.001
ALD + HBV
No AVT + no abst	100/194 (51.5)	1
No AVT + abst	41/158 (25.9)	0.33	0.21–0.52	< 0.001
AVT + no abst	9/32 (28.1)	0.37	0.16–0.84	0.017
AVT + abst	5/33 (15.2)	0.17	0.06–0.45	< 0.001
ALD + HCV
No AVT + no abst	25/36 (69.4)	1
No AVT + abst	5/18 (27.8)	0.17	0.05–0.59	0.005
AVT + no abst	32/51 (62.7)	0.74	0.30–1.84	0.518
AVT + abst	4/25 (16.0)	0.08	0.02–0.30	< 0.001

Only patients with information on AVT were included in this analysis
EGVB, esophageal gastric variceal bleeding; AVT, antiviral treatment; abst, alcohol abstinence; HBV, hepatitis B virus; HCV, hepatitis C virus; ALD, alcohol-induced liver disease; ALD + HCV, co-existing ALD and HCV.

ISSN: 1471-230X